Molecular Partners

Another four IPOs complete busy week as biotech raise continues to match 2020's record pace
Another four IPOs complete busy week as biotech raise continues to match 2020's record pace
Endpoints
IPOs
Lyell Immunopharma
Verve Therapeutics
Molecular Partners
ATAI Life Sciences
Century Therapeutics
Ambrx
Cyteir Therapeutics
Flag link:
Molecular Partners prices $64M IPO, falling short of original goal
Molecular Partners prices $64M IPO, falling short of original goal
Fierce Biotech
Molecular Partners
IPOs
Flag link:
Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment
Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment
Biopharma Reporter
Novartis
Molecular Partners
ensovibep
COVID-19
clinical trials
Flag link:
Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies
Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies
BioSpace
Molecular Partners
IPOs
Flag link:
Novartis taps Molecular Partners for a new way to defeat COVID-19
Novartis taps Molecular Partners for a new way to defeat COVID-19
Fierce Biotech
Novartis
Molecular Partners
antivirals
MP0420
MP0423
COVID-19
Flag link:
FDA rejects AbbVie's eye drug, citing safety concerns
FDA rejects AbbVie's eye drug, citing safety concerns
BioPharma Dive
Allergan
AbbVie
FDA
abicipar
Molecular Partners
wet age-related macular degeneration
Flag link:
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Flag link:
Amgen pays $50M for Molecular Partners’ preclinical bispecific
Amgen pays $50M for Molecular Partners’ preclinical bispecific
Fierce Biotech
Amgen
Molecular Partners
MP0310
Flag link:
Roche backs out of its $1B cancer deal with Molecular Partners
Roche backs out of its $1B cancer deal with Molecular Partners
Fierce Biotech
Roche
Molecular Partners
DARPin
R&D
Flag link:
Actavis keeps its Phase III promise with Molecular Partners' eye drug
Actavis keeps its Phase III promise with Molecular Partners' eye drug
Fierce Biotech
Actavis
Molecular Partners
abicipar
wet age-related macular degeneration
Flag link:
Roche teams with Molecular Partners on armed proteins in $1B-plus deal
Roche teams with Molecular Partners on armed proteins in $1B-plus deal
Fierce Biotech
Roche
Molecular Partners
DARPin
Flag link:
Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline
Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline
Fierce Biotech
Allergan
ophthalmology
Molecular Partners
Flag link:
Swiss Biotech IPOs May Revive Industry Starved of Investment
Swiss Biotech IPOs May Revive Industry Starved of Investment
Bloomberg
IPOs
Roche
Novartis
Actelion
Molecular Partners
Newron Pharma
Switzerland
Flag link:
Allergan licenses retinal disease treatment from Molecular Partners in $420 million deal
Allergan licenses retinal disease treatment from Molecular Partners in $420 million deal
Yahoo/AP
Allergan
Molecular Partners
retinal disease
Flag link: